中国2型糖尿病防治指南解读教学材料.ppt

数个研究证明 诺和锐30每日两次显著降糖，可以使患者治疗达标 再来看下两组糖化血红蛋白具体的控制情况，诺和锐?30治疗组HbA1c较基线下降了2.79，而甘精胰岛素组下降了2.36，两组有明显的统计学意义。值得注意的是，两组空腹血糖的控制是相似的，也就是说，相比甘精胰岛素，诺和锐?30可以更加全面的控制血糖。 ANA 038 Summary: At 12 weeks, mean prandial glucose excursion was significantly less (p < 0.02) in the NovoMix 30 group compared with the BHI 30 group. Postprandial glycaemic control was significantly better with NovoMix? 30 when analysed on the basis of mean prandial blood glucose increment - mean increment (post-meal minus pre-meal blood glucose) over the three meals including lunch, when no insulin was given. After 12 weeks, mean prandial glucose increment was 1.66 ± 0.20 mmol/l in the NovoMix? 30 group versus 2.34 ± 0.19 mmol/l for BHI 30 (p < 0.02). After three months treatment, levels of HbA1c did not differ between the two treatment groups. Only subjects who had a complete set of values for each of the 8-point blood glucose time points were included in the analysis. 与人胰岛素30R相比，诺和锐30组： 主要低血糖事件发生率少一半 较少的轻度夜间低血糖事件 0－5h：餐后0－5小时的血糖波动 0－2h：餐后0－2小时的血糖波动 2－5h：餐后2－5小时的血糖波动 OBJECTIVE— The rapid-acting insulin analogs aspart and lispro have now been developed in biphasic formulations. This trial compared the postprandial serumglucose control of biphasic insulin aspart 30 (BIAsp 30: 30% aspart, 70% protaminated aspart) with that of biphasic insulin lispro 25 (Mix25: 25%lispro, 75%protaminated lispro) and biphasic human insulin 30 (BHI 30:30% regular insulin, 70% NPH insulin) in insulin-treated subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS— This was an open-labeled, randomized, single-dose, three-way crossover trial of 61 insulin-treated subjects with type 2 diabetes who had no signi?cant late diabetic complications. BIAsp 30 and Mix25 were injected subcutaneously immediately before a test meal, and BHI 30 was injected 15 min before a test meal. The primary target of analysis was serum glucose excursion 0–5 h after a meal. RESULTS— The postprandial glycemic control with BIAsp 30, as assessed by th